Red­Hill's an­tibi­ot­ic Tal­i­cia edges clos­er to ap­proval, af­ter sec­ond suc­cess­ful Phase III study

As one of the few com­pa­nies fo­cus­ing on tack­ling the bur­geon­ing threat of su­per­bugs, Is­rael’s Red­Hill Bio­phar­ma $RDHL is mak­ing strides. On Mon­day, it said its ex­per­i­men­tal drug Tal­i­cia was suc­cess­ful in erad­i­cat­ing the H. py­lori in­fec­tion, meet­ing the main goal of a sec­ond Phase III study.

The da­ta are com­pelling enough for the com­pa­ny to sub­mit an ap­pli­ca­tion to mar­ket the drug in 2019 for the es­ti­mat­ed 2.5 mil­lion pa­tients treat­ed for the in­fec­tion each year in the Unit­ed States.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER